Abstract | BACKGROUND: OBJECTIVE: METHODS AND DESIGN: The Efficacy and Safety of Tirofiban Compared with Aspirin in the Treatment of Acute Ischemic Stroke (RESCUE BT 2) Trial is an investigator-initiated, prospective, randomized, double-blind, double-dummy, multicenter clinical trial. Up to 1158 eligible patients will be consecutively randomized to receive antiplatelet therapy with tirofiban or aspirin in 1:1 ratio across approximately 100 stroke centers in China. OUTCOMES: The primary endpoint is the proportion of patients with excellent functional outcomes defined as a modified Rankin scale score of 0 to 1 at 90 days after randomization. Lead safety endpoints include mortality at 90 days and symptomatic intracerebral hemorrhage within 48 h after treatment. TRIAL REGISTRY NUMBER: ChiCTR2000029502 (www.chictr.org.cn).
|
Authors | Wenjie Zi, Jiaxing Song, Zhongming Qiu, Weilin Kong, Jiacheng Huang, Weidong Luo, Shuai Liu, Hongfei Sang, Jie Yang, Linyu Li, Yan Tian, Jinrong Hu, Jeffrey L Saver, Raul G Nogueira, Fengli Li, Qingwu Yang |
Journal | International journal of stroke : official journal of the International Stroke Society
(Int J Stroke)
Vol. 18
Issue 5
Pg. 620-625
(06 2023)
ISSN: 1747-4949 [Electronic] United States |
PMID | 35993176
(Publication Type: Randomized Controlled Trial, Multicenter Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Tirofiban
- Platelet Aggregation Inhibitors
- Tyrosine
- Aspirin
|
Topics |
- Humans
- Tirofiban
(therapeutic use)
- Platelet Aggregation Inhibitors
(adverse effects)
- Stroke
- Ischemic Stroke
(drug therapy)
- Prospective Studies
- Tyrosine
(therapeutic use)
- Aspirin
(therapeutic use)
- Double-Blind Method
- Treatment Outcome
|